Atrial fibrillation and risk

Clin Cardiol. 2012 Jan;35 Suppl 1(Suppl 1):1-2. doi: 10.1002/clc.21961.

Abstract

Dr. Camm received an honorarium through an educational grant from Sanofi Aventis to serve as Guest Editor of this supplement. He discloses no other direct conflicts of interest to the submitted work. Dr. Camm has served as a consultant, received grant funding, and has been a member of the speakers bureau for Sanofi Aventis.

Publication types

  • Introductory Journal Article

MeSH terms

  • Atrial Fibrillation / complications*
  • Atrial Fibrillation / therapy
  • Humans
  • Prognosis
  • Risk Assessment
  • Risk Factors
  • Stroke / etiology*
  • Stroke / prevention & control
  • Thromboembolism / etiology*
  • Thromboembolism / prevention & control